Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On April 3, 2023, we reported on a study published in The BMJ that examined whether postpartum maternal opioid treatment is associated with short-term increased risk of adverse outcomes in infants.
The study
Researchers analyzed 8 years of health care data obtained from the ICES MOMBABY database, which links children born in Ontario hospitals to their mothers. They also used the Narcotics Monitoring System and the National Ambulatory Care Reporting System databases to identify prescriptions for postpartum opioids. Participants included 865 691 mother-infant pairs discharged from the hospital within 7 days of delivery between September 1, 2012, and March 31, 2020. Researchers identified 85 852 mothers who had filled an opioid prescription between delivery and up to 7 days after being discharged from the hospital. Each mother who filled an opioid prescription was propensity score matched to one who did not fill an opioid prescription. Opioids prescribed included oxycodone, codeine, morphine, and hydromorphone, with an average supply of 3 days.
The primary outcome was hospital readmission of infants for any reason within 30 days of their mother filling an opioid prescription. Secondary outcomes included any emergency department visit, hospital admission for any injury, admission to the neonatal intensive care unit, hospital admission with resuscitation or assisted ventilation, and all-cause death.
The results
Of the infants admitted to the hospital within 30 days of birth, 2962 (3.5%) were born to mothers who filled an opioid prescription and 3038 (3.5%) were born to mothers who did not fill an opioid prescription.
Infants of mothers who were prescribed an opioid were more likely to be admitted to the hospital for any reason than infants of mothers who were not prescribed an opioid (hazard ratio [HR] 0.98, 95% CI 0.93-1.03) and slightly more likely to be taken to an emergency department in the subsequent 30 days (HR 1.04, 95% CI 1.01-1.08). There were no differences between the 2 groups in all other secondary outcomes, and no deaths occurred in either group.
Note from authors
"This study found no association between maternal opioid prescription after delivery and several adverse infant outcomes, including death. Although we endorse caution in short term postpartum opioid use in selected mothers, clinicians and parents should be reassured that infants are at low risk of harm."
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.